+ Watch GERN
on My Watchlist
A biopharmaceutical company which is developing first-in-class therapeutic products for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS.
A few of these speculative, somewhat broken biopharm are spiking nicely the last few months. Calling a top without more DD could be short term dangerous. Geron Corp has doubled from it's June lows. Typically half or more of the "investors" lately are trading, speculating, or covering ill-timed shorts. They are not loyal and the other half are more careful of late to protect profits. Six reports over the next six to nine months might give this one some staying power, as can "rumors" of partnerships.A less toxic chemo drug delivery system seems promising, but also seems difficult to correlate and time consuming to study. Since Geron backed of their stem cell testing and focused more on cancer research, down playing the pops is more risky. Cash burn rate and cash position seem relatively strong although many biopharms sell into strength anyway. This might have made a good speculative up-play at $1.30 as insiders did. Overall, I'm not supporting the market cap at this stage. Short term call, looking for pullback as time progresses.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions